Literature DB >> 30674721

Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche.

Sara Chiblak1,2, Zili Tang1,2, Dieter Lemke1,3, Maximilian Knoll1,2, Ivana Dokic1,2, Rolf Warta1,4, Mahmoud Moustafa1,2, Walter Mier1,5, Stephan Brons2, Carmen Rapp1,4, Stefan Muschal1,2, Philipp Seidel1,2, Martin Bendszus1,3, Sebastian Adeberg1,2, Otmar D Wiestler1, Uwe Haberkorn1,5, Jürgen Debus1,2, Christel Herold-Mende1,4, Wolfgang Wick1,3, Amir Abdollahi1,2.   

Abstract

Tumor radioresistance leading to local therapy failure remains a major obstacle for successful treatment of high-grade glioma. We hypothesized that distinct radiobiological features of particle therapy with carbon ions may circumvent glioma radioresistance. We demonstrate that carbon irradiation (CIR) efficiently eradicates radioresistant patient-derived glioma stem cells (GSCs), leading to growth inhibition and prolonged survival. The impact of CIR at the tumor-stroma interface was further investigated in 2 syngeneic mouse and 2 orthotopic GSC xenograft models. Intriguingly, tumor regressions and long-term local controls were observed at doses greater than or equal to 15-Gy CIR. Fractionated CIR further prolonged survival. The enhanced relative biological effectiveness of CIR in vivo was attributed to its potent antiangiogenic effects and eradication of radioresistant hypoxic tumor cells. Blockade of the HIF1-α/stromal cell-derived factor 1/CXCR4 axis by CIR reduced the recruitment of microglia and myeloid-derived suppressor cells (CD11b+Gr1+). Consequently, CIR abrogated M2-like immune polarization and enhanced the influx of CD8+ cells, generating an immunopermissive niche. We report that radiotherapy with carbon ions could surmount several central glioma resistance mechanisms by eradicating hypoxic and stem cell-like tumor cells, as well as modulating the glioma niche toward an antiangiogenic and less immunosuppressive state. Conclusively, potentially novel rationales for CIR in conquering glioma radioresistance are provided.

Entities:  

Keywords:  Brain cancer; Mouse models; Oncology; Therapeutics

Year:  2019        PMID: 30674721      PMCID: PMC6413779          DOI: 10.1172/jci.insight.123837

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  23 in total

1.  Potential role of carbon ion radiotherapy in chromothripsis-induced medulloblastoma and other malignancies.

Authors:  Gregory K Friedman; Girish Dhall
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

2.  Different Mechanisms Underlie the Metabolic Response of GBM Stem-Like Cells to Ionizing Radiation: Biological and MRS Studies on Effects of Photons and Carbon Ions.

Authors:  Alessandra Palma; Sveva Grande; Lucia Ricci-Vitiani; Anna Maria Luciani; Mariachiara Buccarelli; Mauro Biffoni; Valentina Dini; Giuseppe A P Cirrone; Mario Ciocca; Laura Guidoni; Roberto Pallini; Vincenza Viti; Antonella Rosi
Journal:  Int J Mol Sci       Date:  2020-07-21       Impact factor: 5.923

3.  Impact of Hypoxia on Carbon Ion Therapy in Glioblastoma Cells: Modulation by LET and Hypoxia-Dependent Genes.

Authors:  Samuel Valable; Aurélie N Gérault; Gaëlle Lambert; Marine M Leblond; Clément Anfray; Jérôme Toutain; Karim Bordji; Edwige Petit; Myriam Bernaudin; Elodie A Pérès
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 4.  Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.

Authors:  Andy S Ding; Denis Routkevitch; Christina Jackson; Michael Lim
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

5.  Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility.

Authors:  Eleanor A Blakely; Bruce Faddegon; Christopher Tinkle; Charles Bloch; Michael Dominello; Robert J Griffin; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-10-01       Impact factor: 2.243

Review 6.  At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Authors:  Gary D Luker; Jinming Yang; Ann Richmond; Stefania Scala; Claudio Festuccia; Margret Schottelius; Hans-Jürgen Wester; Johann Zimmermann
Journal:  J Leukoc Biol       Date:  2020-10-26       Impact factor: 4.962

Review 7.  MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.

Authors:  Xanthene Miles; Charlot Vandevoorde; Alistair Hunter; Julie Bolcaen
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

8.  Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Authors:  Wei Wu; Jessica L Klockow; Michael Zhang; Famyrah Lafortune; Edwin Chang; Linchun Jin; Yang Wu; Heike E Daldrup-Link
Journal:  Pharmacol Res       Date:  2021-07-21       Impact factor: 10.334

Review 9.  Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?

Authors:  Camille Huart; Jia-Wei Chen; Benjamin Le Calvé; Carine Michiels; Anne-Catherine Wéra
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 6.208

Review 10.  Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance.

Authors:  Sabbir Khan; Sandeep Mittal; Kain McGee; Kristin D Alfaro-Munoz; Nazanin Majd; Veerakumar Balasubramaniyan; John F de Groot
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.